ALK Positive NSCLC - Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose. The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.

See detailed information including eligibility.

Cancer, Adult Lung Cancer